Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07165743 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Fetal Bladder Emptying During the 11-14 Weeks' Ultrasound Examination as a Negative Predictive Marker for Chromosomal Abnormalities

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 10, 2025 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Minor Study First Submitted
Template-Based Brief Summary (Sağlık Profesyonelleri İçin) Study Title: The Negative Predictive Value of First-Trimester Fetal Bladder "Rapid Emptying" (≤40 minutes and post-void ≤2 mm) for Major Chromosomal Aneuploidies: A Prospective Diagnostic Accuracy Study. Purpose: To evaluate whether the dynamic phenotype of rapid bladder emptying at 11-14 weeks reduces the likelihood of major chromosomal abnormalities (particularly Trisomy 21) compared to fetuses without this phenotype. Design: Single-center, prospective observational cohort. Population: 270 singleton pregnancies between 11+0 and 14+0 weeks. Procedures: Real-time sagittal ultrasound observation for 40 minutes. Documentation of bladder emptying time and post-void longitudinal bladder diameter. Concurrent measurement of CRL, NT, ductus venosus waveform. Gold standard confirmation with cfDNA or invasive karyotyping in high-risk cases. Primary Endpoint: Negative predictive value (NPV), ROC-AUC, sensitivity/specificity for aneuploidy detection. Secondary Endpoints: Rate of invasive testing, performance in combined models with cfDNA and biophysical markers, Net Reclassification Index. Duration: 5 months (08/2025 - 01/2026). Potential Impact: If validated, the rapid emptying phenotype may serve as a low-risk marker, reduce unnecessary invasive procedures, and refine first-trimester screening algorithms.
Trial Details
NCT Number NCT07165743
Lead Sponsor Haseki Training and Research Hospital
Conditions
(from sponsor)
Chromosomal Aneuploidies (e.g., Trisomy 21, Trisomy 18, Trisomy 13); Prenatal Screening Accuracy
Related terms Down Syndrome, Trisomy 13 Syndrome, Trisomy 18 Syndrome
Enrollment 270 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov